Study of Oral ELND005 in Patients With Alzheimer’s Disease

• Research type

  Research Study

• Full title

  A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer’s Disease

• IRAS ID

  120788

• Contact name

  Roy Jones

• Contact email

  r.w.jones@bath.ac.uk

• Sponsor organisation

  Elan Pharma International Limited

• Eudract number

  2012-004299-20

• Clinicaltrials.gov Identifier

  NCT01735630

• REC name

  South Central - Hampshire A Research Ethics Committee

• REC reference

  13/SC/0120

• Date of REC Opinion

  25 Apr 2013

• REC opinion

  Further Information Favourable Opinion